ONCO רווחיות מכירות גולמית Onconetix Inc

Gross profit margin on the GURU.Markets chart reveals the pricing power of Onconetix, Inc. (ONCO) in urology driven by Proclarix software. The current figure stands at 73.80, which, despite patents, is constrained by high competition. Meanwhile, intellectual property in oncology provides the company with global scaling potential and ultra-high future returns.
פילוחי מדדים מקיפים ואנליטיקה עבור Onconetix (ONCO)

For Onconetix, Inc. (ONCO), patent protection of biomarkers serves as the key barrier to safeguarding profits amid fierce competition in oncology diagnostics. This metric is calculated as the difference between total revenue and direct test production costs, expressed as a percentage of revenue. An analysis of this model's efficiency and the risks of technological obsolescence in business processes is conducted by monitoring the stability of the gross margin.